Lenaig Le Clech

Brest, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.

Journal: British journal of haematology
Published: March 28, 2025

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Journal: HemaSphere
Published: March 17, 2025

Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell Clones.

Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell Clones.

Journal: American journal of hematology
Published: October 15, 2024

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

Journal: British journal of haematology
Published: May 02, 2024

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

Journal: American journal of hematology
Published: November 10, 2023

Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms.

Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms.

Journal: Thrombosis research
Published: March 07, 2022

Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis.

Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis.

Journal: Haematologica
Published: February 24, 2022

The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.

The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.

Journal: Infectious diseases now
Published: January 03, 2022

Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.

Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.

Journal: Annals of hematology
Published: October 05, 2021

Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders.

Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders.

Journal: Annals of hematology
Published: April 05, 2021

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.

Journal: British journal of haematology
Published: February 02, 2021

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Journal: Haematologica
Published: September 17, 2020
Showing 1-12 of 22

Last Updated: 09/26/2026